News about Clinical Trials

Inventiva and Hepalys Pharma Initiate Clinical Development Program of Lanifibranor in Japan

The trial is conducted pursuant to the terms of the exclusive licensing agreement entered into in 2023 between Inventiva and Hepalys to develop and commercialize lanifibranor in Japan and South Korea.

Clinical Trials | 21/02/2025 | By Aishwarya |  685

AlzeCure Gets EU Grant for Phase 2 Clinical Trial of NeuroRestore ACD856

This funding will support AlzeCure’s planned Phase IIa study of NeuroRestore ACD856 in Alzheimer’s patients.

Clinical Trials | 19/02/2025 | By Aishwarya |  555

Selkirk Pharma Launches ClinFAST to Expedite Fill/Finish for Clinical Trials

Selkirk Pharma maintains an on-site inventory of ISO-sized vials, stoppers, filling assemblies, and excipients, reducing the lead time required for sourcing materials.

Clinical Trials | 14/02/2025 | By Aishwarya |  528

Philogen Completes Patient Enrollment of Phase III FIBROSARC Trial in STS

All ongoing Fibromun trials remain on track with their expected timelines.

Clinical Trials | 05/02/2025 | By Aishwarya |  1067

Exigent Research and ConcertAI to Integrate CARAai Precision Trial Solutions

The technology suite will be tailored and fully integrated to all Exigent sites and all EMRs and powered by the CARAai™ platform.

Clinical Trials | 04/02/2025 | By Aishwarya |  498

Renalys Pharma Completes Patient Enrollment for Phase III Trial of Sparsentan in Japan

In April 2024 Renalys submitted an Investigational New Drug (IND) Application for sparsentan to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.

Clinical Trials | 01/02/2025 | By Abha |  734

Corsair Pharma Collaborates with InstantGMP to Enhance Quality for Clinical Trials

Corsair Pharma is revolutionizing pulmonary arterial hypertension (PAH) treatment with its first product candidate: a prodrug of treprostinil delivered via a proprietary transdermal patch.

Clinical Trials | 30/01/2025 | By Aishwarya |  347

Tris Pharma Reveals Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol

This dual-NMR agonist has the potential to deliver significant pain relief comparable to opioids with minimized risk of significant side effects, dependence and addiction by leveraging the body’s pain biology modulation processes, synergizing the analgesic and safety characteristics of the NOP receptor with the analgesic advantages of the MOP receptor.

Clinical Trials | 23/01/2025 | By Aishwarya |  627

Advarra Launches Comprehensive Solution to Improve Collaboration on Clinical Trials

The new offering combines the Longboat technology acquired by Advarra in 2020, which now has over 225,000 users, with Advarra's study startup delivery program and industry-adopted single sign-on capabilities.

Clinical Trials | 22/01/2025 | By Aishwarya |  898

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

The company successfully completed an FDA-recommended study of isomyosamine that demonstrated clinical safety throughout 13 weeks of treatment at all dose levels evaluated.

Clinical Trials | 16/01/2025 | By Aishwarya |  562